Discon Plus (Etafilcon A) Contact Lens visibility tint with UV blocker is indicated for daily wear for the correction of refractive ametropia in not-aphakic persons with non-diseased eyes that are myopic or hyperopic and may exhibit refractive astigmatism up to 2.00 diopters that does not interfere with visual acuity.

Eye care practitioners may prescribe the lenses for either single-use daily disposable wear or frequent/planned replacement wear with cleaning, rinsing, disinfection and scheduled replacement as prescribed by the eyecare professional. When prescribed for frequent/planned replacement wear. The contact lens may be disinfected using chemical (not heat) disinfection system.

Device Description

The Discon Plus (Etafilcon A) Contact Lens visibility tint with UV blocker is available as non-spherical fenses manufactured by spin-casting method. The model illuminated with high water content (58 %). `.te hydrogel lens' material is a random copolymer composed of 2-hydroxyethyl methacrylate (HEMA) Ind methacrylic acid (MAA), which was cross-linked with 1,1,1-trimethylolpropane trimethacrylate (TMPTMA) and Ethylene Glycol Dimethacrylate (EGDMA) via UV photo- polymerization. The Discon Plus (Etafilcon A) Contact Lens visibility tint with UV blocker is tinted blue using C.I Reactive blue 19 to make the lens more visible for handling In the Discon Plus Contact Lens with UV Blocker, a Benzophenone UV absorbing monomer is used to block UV radiation. The average transmittance characteristics for Discon Plus lens are less than 5% in the UVB range of 280nm - 315nm and less than 30% in the UVA range of 316nm - 380nm. Lenses are supplied sterile in sealed blister packers containing sterile isotonic phosphate buffered saline solution.

AI/ML Overview

This document describes the Discon Plus (Etafilcon A) Contact Lens visibility tint with UV blocker. It is important to note that this 510(k) submission primarily relies on substantial equivalence to previously cleared predicate devices, rather than an independent de novo study with acceptance criteria being met by the device itself.

1. Table of Acceptance Criteria (Technological Characteristics) and Reported Device Performance

The acceptance criteria are implicitly defined by the properties of the predicate devices. The "reported device performance" refers to the characteristics of the Discon Plus lens, which are shown to be substantially equivalent to the predicates.

Characteristic	Acceptance Criteria (Predicate: Discon (K051129) & Acuvue (K962804))	Reported Device Performance (Discon Plus)
FDA group #	Group # 4 >50% Water, Ionic Polymers	Group # 4 >50% Water, Ionic Polymers
USAN name	Etafilcon A	Etafilcon A
Production method	Predicate 1 (Discon): Spin-casting Predicate 2 (Acuvue): Cast-molded	Spin-casting
%Water content	58	58
Refractive index	1.40	1.40
Oxygen permeability (edged corrected) @ 35°C	Predicate 1 (Discon): $24 \times 10^{-11}$ Predicate 2 (Acuvue): $26 \times 10^{-11}$	$24 \times 10^{-11}$
Power, Diopters	Predicate 1 (Discon): +6.0D~-12.0D Predicate 2 (Acuvue): +20.0D~-20.0D	+20.0D~-20.0D
%Light transmission @381~700 nm	93 minimum (for Discon) / 85 minimum (for Acuvue)	93 minimum
%Light transmission @316~380 nm (UVA)	avg <30% (for Acuvue)	avg <30%
%Light transmission @280~315 nm (UVB)	avg <5% (for Acuvue)	avg <5%

Note regarding "Acceptance Criteria": For this 510(k) submission, the "acceptance criteria" are not explicit numerical targets set for the new device in a de novo study. Instead, the new device (Discon Plus) is deemed acceptable if its characteristics are shown to be "substantially equivalent" to the existing predicate devices. Therefore, the predicate device characteristics serve as the de facto acceptance criteria.

2. Sample Size Used for the Test Set and Data Provenance

The document states: "Therefore, no clinical data is required for this submission." This indicates that no dedicated clinical test set was used for the Discon Plus lens in this specific submission. The clinical safety data is referenced from the predicate device (K051129).

3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications

Since no dedicated clinical test set was used for the Discon Plus lens in this submission, no experts were used to establish ground truth for a test set. The reliance is on prior approvals and established safety profiles of the predicate devices.

4. Adjudication Method for the Test Set

Not applicable, as no dedicated clinical test set was used for the Discon Plus lens in this submission.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

No MRMC comparative effectiveness study was mentioned or performed for this device. This submission focuses on chemical composition and physical properties for substantial equivalence, not on human reader performance with or without AI assistance.

6. Standalone (Algorithm Only) Performance Study

Not applicable. This device is a contact lens and does not involve an algorithm or AI.

7. Type of Ground Truth Used (for "test set")

As stated, no dedicated clinical test set with a newly established ground truth was used for the Discon Plus lens in this submission. The "ground truth" for safety and effectiveness is derived from the previously established safety and effectiveness profiles of the predicate devices (Discon K051129 and Acuvue K962804) and non-clinical testing.

8. Sample Size for the Training Set

Not applicable. This device is a contact lens and does not involve AI or algorithms that would require a training set.

9. How the Ground Truth for the Training Set Was Established

Not applicable. As above, no training set was used.

Summary

{0}------------------------------------------------

510 (K) Summary

SUMMARY OF SAFETY AND EFFECTIVENESS FOR Discon Plus (Etafilcon A) Contact Lens visibility tint with UV blocker

	Submitter Information:	SEP - 3 2009
Company:	INNOVA VISION INC.
	No. 231-1, Wen-Te Road, Chiung-lin Village, Hsin-Chu County, Taiwan.
Contact Person:	Mr. Michael w. Hsu,
	Executive Vice President
Phone:	886-3-592-7299
FAX:	886-3-592-6213
E-Mail:	mikehsu@innovavision.com.tw
Date Prepared	Sept. 20, 2008

Identification of Device:

Classification Name:	Soft hydrophilic contact lens, per 21 CFR. 886.5925
Trade Name:	Discon Plus (Etafilcon A) Contact Lens visibility tint with UV blocker
Common or usual Name:	Soft (hydrophilic) Contact lens (daily wear)
FDA Classification:	Class II

Predicate Device:

Discon (Etafilcon A) Soft (hydrophilic) Contact Lens for Daily Wear cleared via K051129 INNOVA VISION INC. Taiwan

ACUVUE (Etafilcon A) Contact Lens clear and visibility tint with UV blocker cleared via K962804 Vistakon, USA

Indications for Use

Discon Plus (Elafilcon A) Contact Lens visibility tint with UV blocker is indicated for daily wear for the correction of refractive ametropia in not-aphakic persons with non-diseased eyes that are myopic or hyperopic and may exhibit refractive astigmatism up to 2.00 diopters that does not interfere with visual acuity.

{1}------------------------------------------------

Description of Device

い

・・。

Summary of Clinical Study

This 510(k) application describes a UV absorbing compound addition to the predicate device -- Discon (Etafilcon A) Soft (hydrophilic) Contact Lens for Daily Wear cleared via K051129 INNOVA VISION INC. There is no change in the manufacturing process, nor the parameter and properties. The clinical data previously submitted in K051129.supports the clinical safety of the subject device. Besides, the UV absorbing compound and UV-blocking ability are equivalent to ACUVUE (Etafilcon A) Contact Lens clear and visibility tint with UV blocker cleared via K962804 Vistakon. Therefore, no clinical data is required or this submission.

Nonclinical Studies

All testing was conducted in accordance with the May 1994 FDA guideline titled Premarket Notification 510(K) Guidance Document for Class IV Contact lenses.

The non-clinical performance tests had been performed to demonstrate the safety and effectiveness of the Discon Plus (Etafilcon A) Contact Lens visibility tint with UV blocker, and establish substantial equivalence to predicate lenses-Discon Lens (K051129); ACUVUE (Etafilcon A) Contact Lens clear and visibility tint with UV blocker (K962804). The evidence of substantial equivalent to the predicate lens described as follow:

{2}------------------------------------------------

a) Technological characteristics studies
・・・

The technological characteristics of Discon Plus (Etafilcon A) Contact Lens visibility tint with UV blocker as compared to those of predicate lenses are illustrated in the following table.

Characteristic	Discon Plus	Discon (K051129)	Acuvue (K962804)
FDA group #	Group # 4>50% Water,Ionic Polymers	Group # 4>50% Water,Ionic Polymers	Group # 4>50% Water,Ionic Polymers
USAN name	Etafilcon A	Etafilcon A	Etafilcon A
Production method	Spin-casting	Spin-casting	Cast-molded
%Water content	58	58	58
Refractive index	1.40	1.40	1.40
Oxygen permeability (edgedcorrected) @ 35°C	$24\times10^{-11}$[(cm²/sec)(mlO²/ml-mmHg)]	$24\times10^{-11}$[(cm²/sec)(mlO²/ml-mmHg)]	$26\times10^{-11}$[(cm²/sec)(mlO²/ml-mmHg)]
Power, Diopters	+20.0D~-20.0D	+6.0D~-12.0D	+20.0D~-20.0D
%Light transmission
%T @381~700 nm	93 minimum	93 minimum	85 minimum
%T @316~380 nm	avg <30%	NA	avg <30%
%T @280~315 nm	avg<5%	NA	avg<5%

'b) Biocompatibility
The following non-clinical tests were conducted as recommended by the Premarket Notification quidance document for Daily Wear Contact Lenses, revised May 1994.
1. Toxicology testing
a. Cytotoxicity
b. USP Ocular Irritation
c. USP Systemic Injection

'c) Microbiology

Steam sterilization process has been validated to deliver a minimum SAL of 10°, thereby complying with the requirement of FDA Group IV. There is shelf-life stability data supporting that the lens remains sterile through the expiration date claimed for the product.

d) Leachability
Studies were conducted to determine the leachable materials from the finished lens. The results show that, at the levels of the detection reported, there are no leachable monomers and addictive residues.

{3}------------------------------------------------

Substantial Equivalence Statement

ﻬﺎ

, l

In conclusion, it is Innova's conviction that data submitted in this 510(k) to validate the claim of > ubstantial equivalency, substantiates our ability to manufacture a soft contact lens, the Discon Plus (Etafilcon A) Contact Lens visibility tint with UV blocker, with the same established safety profile and effectiveness as the predicate device-- Discon (Etafilcon A) Soft (hydrophilic) Contact Lens for Daily Wear cleared via K051129 & ACUVUE (Etafilcon A) Contact Lens clear and visibility tint with UV blocker cleared via K962804.

{4}------------------------------------------------

Image /page/4/Picture/1 description: The image contains the logo for the Department of Health & Human Services (HHS) in the United States. The logo features the department's emblem, which consists of a stylized caduceus-like symbol with three blue lines representing the three aspects of the department's mission: health, human services, and science. The emblem is encircled by the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" in a circular arrangement.

Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-G609 Silver Spring, MD 20993-0002

MAR 2 3 2010

Innova Vision, Inc. c/o Harvest Consulting Corp. Ms. Jennifer Reich Senior Consultant 2904 N. Boldt Drive Flagstaff, AZ 86001

Re: K083288

Trade/Device Name: Discon Plus (etafilcon A) Contact Lens visibility tint with UV blocker Regulation Number: 21 CFR 886.5925 Regulation Name: Soft (hydrophilic) Contact Lens Regulatory Class: II Product Code: LPL, MVN Dated: August 12, 2009 Received: August 18, 2009

Dear Ms. Reich:

This letter corrects our substantially equivalent letter of September 3. 2009.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices. good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21

{5}------------------------------------------------

CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Kesia Alexander for

Malvina B. Evdelman, M.D. Director Division of Ophthalmic, Neurological, and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health

{6}------------------------------------------------

INDICATIONS FOR USE STATEMENT

'10(k) Number: K083>88

Device Name: Discon Plus (Etafilcon A) Contact Lens visibility tint with UV blocker

Indications for Use:

Concurrence of CDRH, Office of Device Evaluation (ODE)

	(Division Sign-Off)
	Division of Ophthalmic Ear,
	Nose and Throat Devices
510(k) Number	K083288

Prescription Use:		or	Over the Counter Use
-------------------	-------------------------------------------	----	----------------------	-------------------------------------------

	(Division Sign-Off)
	Division of Ophthalmic, Neurological and Ear,
	Nose and Throat Devices
510(k) Number	K083288

Regulation Number and Section

§ 886.5925 Soft (hydrophilic) contact lens.

(a)
Identification. A soft (hydrophilic) contact lens is a device intended to be worn directly against the cornea and adjacent limbal and scleral areas of the eye to correct vision conditions or act as a therapeutic bandage. The device is made of various polymer materials the main polymer molecules of which absorb or attract a certain volume (percentage) of water.(b)
Classification. (1) Class II if the device is intended for daily wear only.(2) Class III if the device is intended for extended wear.
(c)
Date PMA or notice of completion of a PDP is required. As of May 28, 1976, an approval under section 515 of the act is required before a device described in paragraph (b)(2) of this section may be commercially distributed. See § 886.3.